Key result
Mechanical circulatory assist devices for end-stage congestive heart failure remain associated with thrombosis due to unresolved issues with material biocompatibility.
Why the study?
Mechanical circulatory assist devices remain associated with dangerous complications such as thrombosis, and creating biocompatible materials remains an unresolved challenge.
Thrombosis remains a significant complication of mechanical circulatory assist devices due to unresolved biocompatibility issues.
Thrombosis risk persists with current LVADs; leaves open the need for advances in biocompatible materials and device design.
Patients suffering from end-stage congestive heart failure are in the severe category of cardiac patients. For many decades, there has been active development of circulatory assist devices. However, despite significant progress made in this area, the use of such devices is associated with several dangerous complications, one of which is thrombosis. The problem of creating biocompatible materials still remains unresolved. Analyzing the mechanism and risk of this complication allows to determine the ways of solving this problem.
No takes yet. Share an insight, caveat, or question.
Zhulkov et al. (2021) conducted a review in End-stage congestive heart failure. Mechanical circulatory assist devices was evaluated. Mechanical circulatory assist devices for end-stage congestive heart failure remain associated with thrombosis due to unresolved issues with material biocompatibility.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: